In Vitro Antiviral Activity of AegleMarmelos against Influenza A (H1N1) Pdm09

  • S.G. Raman Department of Pharmaceutical Chemistry, School of Pharmacy, Sri Balaji Vidyapeeth Deemed to be University, Puducherry- 607402.
  • I. Sarath Chandiran Department of Pharmaceutics, School of Pharmacy, Sri Balaji Vidyapeeth Deemed to be University, Puducherry- 607402.

Abstract

Due to the high prevalence of viral infections having no specific treatment and the constant appearance of resistant viral strains, the development of novel antiviral agents is essential. The aim of this study was to evaluate the antiviral activity of aqueous and ethanolic extracts of Aeglemarmelosagainst Influenza A (H1N1) pdm09. The extract was subjected to cytotoxicity as well as antiviral activity on MDCK cells. The concentration range from 10 to 100μg/ml in MDCK cell line was conducted. It showed that the treated cells with drug was nontoxic to the cells at the concentration of 50μg/ml for ethanolic and 60μg /ml for aqueous extract at 48 hrs to 72 hrs and was comparable to that of controls. Hence crude extract of both ethanolic and aqueous up to 50-60μg /ml (CC50) could be used to test the antiviral activity without affecting much of the cell viability. In simultaneous anti viral assay, 80% viral inhibition was observed at the concentration of 50μg/ml in aqueous extract whereas 100 % viral inhibition was observed in ethanolic extract at concentration of 60μg/ml. In the post treatment assay, the aqueous extract did not show viral inhibition, whereas the ethanolic extract showed 100% reduction at the concentrations of 60μg/ml. This data suggest that ethanolic extract inhibit the Influenza virus infection by blockage of viral attachment by inhibition of viral HA protein, this is consistent with previous studies.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

1. Wood JM, Williams M. History of inactivated influenza vaccines; in Nicholson KG, Webster RG, Hay AJ. (eds): Textbook of Influenza. Oxford: Blackwell Science, 1998;317–323.
2.Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005;23:2943–2952.
3. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, García‐Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999;73:9679–9682.
4. Nicholson JG, Colegate AC, Podda A et al. Safety and antigenicity of non‐adjuvanted and MF59‐adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937–1943.
5. Beare AS, Schild GC. Trials in man with live recombinants made from A/PR/8/34 (H0N1) and wild H3N2 influenza viruses. Lancet 1975;18:729–732.
6 Florent G. RNAs of influenza virus recombinants derived from parents of known virulence for man. Arch Virol 1977;54:19–28.
7. Webby RJ, Perez DR, Coleman JS et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004;363:1099–1103.
8. Docherty JJ, Sweet T, Bailey, Faith B, and Booth T, “Resveratrol inhibition of varicella-zoster virus replication in vitro,” Antiviral Research, vol. 72, no. 3, pp. 171–177, 2006.
9.Gulcin I, “Antioxidant properties of resveratrol: a structure-activity insight,” Innovative Food Science and Emerging Technologies, vol. 11, no. 1, pp. 210–218, 2010.
10.Chen X, Qiao H, Liu T , “Inhibition of herpes simplex virus infection by oligomericstilbenoids through ROS generation,” Antiviral Research, vol. 95, no. 1, pp. 30–36, 2012.
Published
30-06-2021
How to Cite
S.G. Raman, & I. Sarath Chandiran. (2021). In Vitro Antiviral Activity of AegleMarmelos against Influenza A (H1N1) Pdm09. International Journal of Research in Pharmaceutical Sciences and Technology, 2(4), 1-4. Retrieved from https://rubatosis.org/journals/index.php/ijrpst/article/view/271
Section
Research Article